» Articles » PMID: 38001822

Overexpression of Glutathione S-Transferases in Human Diseases: Drug Targets and Therapeutic Implications

Overview
Date 2023 Nov 25
PMID 38001822
Authors
Affiliations
Soon will be listed here.
Abstract

Glutathione S-transferases (GSTs) are a major class of phase II metabolic enzymes. Besides their essential role in detoxification, GSTs also exert diverse biological activities in the occurrence and development of various diseases. In the past few decades, much research interest has been paid to exploring the mechanisms of GST overexpression in tumor drug resistance. Correspondingly, many GST inhibitors have been developed and applied, solely or in combination with chemotherapeutic drugs, for the treatment of multi-drug resistant tumors. Moreover, novel roles of GSTs in other diseases, such as pulmonary fibrosis and neurodegenerative diseases, have been recognized in recent years, although the exact regulatory mechanisms remain to be elucidated. This review, firstly summarizes the roles of GSTs and their overexpression in the above-mentioned diseases with emphasis on the modulation of cell signaling pathways and protein functions. Secondly, specific GST inhibitors currently in pre-clinical development and in clinical stages are inventoried. Lastly, applications of GST inhibitors in targeting cell signaling pathways and intracellular biological processes are discussed, and the potential for disease treatment is prospected. Taken together, this review is expected to provide new insights into the interconnection between GST overexpression and human diseases, which may assist future drug discovery targeting GSTs.

Citing Articles

Investigation of the inhibitory effects of the telomere-targeted compounds on glutathione S-transferase P1.

Ozcan M, Burus A, Mender I, Dikmen Z, Gryaznov S, Bastug T Naunyn Schmiedebergs Arch Pharmacol. 2025; .

PMID: 39954068 DOI: 10.1007/s00210-025-03882-w.


Analysis of microarray and single-cell RNA-seq identifies gene co-expression, cell-cell communication, and tumor environment associated with metabolite interconversion enzyme in prostate cancer.

Hashemi Karoii D, Abroudi A, Forghani N, Bavandi S, Djamali M, Baghaei H Discov Oncol. 2025; 16(1):177.

PMID: 39946051 PMC: 11825437. DOI: 10.1007/s12672-025-01926-4.


Isozyme-specific inhibition of GSTP1-1: a crucial element in cancer-targeting drugs.

Al-Najjar B, Helal M, Saqallah F, Bandy B RSC Med Chem. 2025; .

PMID: 39917632 PMC: 11795191. DOI: 10.1039/d4md00872c.


Toxicity and Oxidative Stress Biomarkers in the Organs of Mice Treated with Mesoporous Polydopamine Nanoparticles Modified with Iron and Coated with Cancer Cell Membrane.

Szukalska M, Grzeskowiak B, Bigaj-Jozefowska M, Witkowska M, Cicha E, Sujka-Kordowska P Int J Nanomedicine. 2024; 19:12053-12078.

PMID: 39583321 PMC: 11585271. DOI: 10.2147/IJN.S481120.


Novel coumarin-6-sulfonamide-chalcone hybrids as glutathione transferase P1-1 inhibitors.

Sabt A, Kitsos S, Ebaid M, Furlan V, Pantiora P, Tsolka M PLoS One. 2024; 19(8):e0306124.

PMID: 39141629 PMC: 11324126. DOI: 10.1371/journal.pone.0306124.


References
1.
Flanagan J, Smythe M . Sigma-class glutathione transferases. Drug Metab Rev. 2011; 43(2):194-214. DOI: 10.3109/03602532.2011.560157. View

2.
Oakley A . Glutathione transferases: a structural perspective. Drug Metab Rev. 2011; 43(2):138-51. DOI: 10.3109/03602532.2011.558093. View

3.
Mohana K, Achary A . Human cytosolic glutathione-S-transferases: quantitative analysis of expression, comparative analysis of structures and inhibition strategies of isozymes involved in drug resistance. Drug Metab Rev. 2017; 49(3):318-337. DOI: 10.1080/03602532.2017.1343343. View

4.
Murgo A . Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist. 2001; 6 Suppl 2:22-8. DOI: 10.1634/theoncologist.6-suppl_2-22. View

5.
Zimniak P . Detoxification reactions: relevance to aging. Ageing Res Rev. 2008; 7(4):281-300. PMC: 2671233. DOI: 10.1016/j.arr.2008.04.001. View